Skip to main content

Academy Calls for Immediate Halt in CMS’ Implementation of Step Therapy

We’re bringing in the attorneys as we continue to press to halt substantial obstacles between patients and their physicians’ recommended treatment options.

The Academy has informed the Centers for Medicare & Medicaid Services that an independent legal review secured by the Academy and our coalition partners indicates potential grounds for litigation following the Jan. 1 start to step therapy in Medicare Advantage. Following an extensive legal review, the Academy, along with an anti-step-therapy coalition that includes the American Society of Retina Specialists and the American Society of Cataract and Refractive Surgery, argue that CMS’ reliance on an Aug. 8, 2018, policy memorandum “does not provide a legally sufficient basis for [Medicare Advantage] plans to implement such programs.”

If CMS proceeds, the Academy believes it immediately exposes its Medicare Advantage program and plans to litigation on behalf of physicians and patients.

This latest action was fueled by a CMS decision in November to use its rulemaking process to expand health plans’ authority to use prior authorization and step therapy for self-administered drugs covered under the Part D program. By codifying its Part D policy via rulemaking, CMS tacitly acknowledged that it erred when it said step therapy is permissible, based in a policy memorandum.

There is compelling evidence that shows how CMS’ step therapy initiative will put the agency in jeopardy on a number of fronts. In spite of the mounting evidence against step therapy, the agency opted to proceed with implementation on Jan. 1.

The Academy and others continue to believe that the following arguments justify the illegality of CMS’ step therapy policy:

  • CMS does not have the authority to grant Medicare Advantage plans the ability to limit coverage for Part B drugs.
  • The plan interferes with beneficiaries’ access to the same services provided under Original Medicare, which is inappropriate. 

CMS is permitting Medicare Advantage plans to require that patients’ treatment start with an off-label option, which would include ophthalmic treatments, such as Avastin.

The agency says the policy allows Medicare Advantage plans the ability to negotiate drug prices, which could lower costs. However, the Academy believes that it instead inserts substantial obstacles between patients and their physicians’ recommended treatment options.

Related Stories

Member exclusive - Locked
Step therapy has to go

Federal Watchdog to Investigate Step Therapy in Medicare Advantage Plans, at Academy’s Urging

The Academy met with the HHS Office of Inspector to continue pressing our concerns about step therapy. The meeting follows the OIG’s September 15 announcement that it will review how Medicare Advantage plans use prior authorization and step therapy for Part B drugs, a review the Academy urged.  
 

Member exclusive - Locked Fallback image

Advocacy Works: Academy Pushes Humana to Correct 1.8 Million Denied Claims

Responding to members, the Academy fought Humana's mass denials and won. Here's what your practice needs to know to recover affected payments.

Member exclusive - Locked Fallback image

Advocacy Works: Humana Backs Down on Claim Denials

When Humana started denying valid claims for office and eye visits billed with diagnostic testing, the Academy fought back — and won.

Latest Updates

Member exclusive - Locked
capital building side

OPHTHPAC Midterms Recap: What the Results Mean for Ophthalmology

The 2026 midterm results are nearly final, and thanks to the support of ophthalmologists nationwide, OPHTHPAC helped secure important victories for ophthalmology this election cycle: 100 of 114 OPHTHPAC-backed candidates won their general election races, with a few results still being finalized. Here is what this year’s results mean for ophthalmology.

Member exclusive - Locked
capital building side

Final Hospital Outpatient, ASC Rule: Pay Raises for Device-Intensive Procedures, But Cuts to Other Common Ophthalmic Surgeries

Hospital outpatient departments (HOPD) and ambulatory surgical centers will get a 2.3% payment increase in 2027. But the rule released Nov. 4 by the Centers for Medicare & Medicaid Services includes hidden reimbursement cuts for most ophthalmology surgeries.

Member exclusive - Locked
HHS

2027 Fee Schedule Finalizes Pay Cut to Physicians Between 1.8% and 2.3%

The final rule from the Centers for Medicare & Medicaid Services (CMS) includes a 2.31% payment cut for physicians not participating in qualifying APMs and a 1.83% pay cut for qualifying Alternative Payment Model (APM) participants.